Vanda Pharmaceuticals Enters into an Exclusive Global License Agreement with AnaptysBio to Develop and Commercialize Imsidolimab
Shots:
- Vanda received exclusive rights to develop, manufacture & commercialize imsidolimab which has completed 2 P-III (GEMINI-1 & GEMINI-2) trials for generalized pustular psoriasis
- As per the terms, Anaptys will get $10M upfront, $5M for existing drug supply, & ~$35M in regulatory & sales milestones, plus 10% royalty on net sales, whereas Vanda will start technology transfer, manufacturing as well as BLA & MAA filings with the FDA & EMA in 2025
- In GEMINI-1, imsidolimab (750/300mg IV, single dose) vs PBO showed 53% vs 13% (750mg) & 53% (300mg) achieved GPPPGA (0/1; 1EP) at 4wks. GEMINI-2 followed 16 responders for 24 - 92wks.: 8 on imsidolimab (200mg, SC, Q1M) with sustained response & no flare; 8 on PBO with 25% sustained & 63% flared
Ref: PRNewswire | Image: AnaptysBio & Vanda Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
